COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,184 Articles (22,713 medRxiv, 8,471 bioRxiv)

Most recent first Previous |  Page 1567: Articles 15661-15670  | Next

Affordable and time-effective high throughput screening of SARS-CoV-2 variants using Denaturing High-Performance Liquid Chromatography analysis
Turba, M. E., Mion, D., Papadimitriou, S., Taddei, F., Dirani, G., Sambri, V., Gentilini, F.
10.1101/2021.04.27.21256156 — Posted: 2021-04-29
Previously infected vaccinees broadly neutralize SARS-CoV-2 variants
Leier, H. C., Bates, T. A., Lyski, Z. L., McBride, S. K., Lee, D. X., Coulter, F. J., Goodman, J. R., Lu, Z., Curlin, M. E., Messer, W. B., Tafesse, F. G.
10.1101/2021.04.25.21256049 — Posted: 2021-04-29 Discussion: Onsite
Antibody response to SARS-CoV-2 infection over six months among Nicaraguan outpatients
Bucardo, F., Gonzalez, F., Zepeda, O., Toval Ruiz, C. T., Matute, A. J., Vanegas, H., Munguia, N., Centeno, E., Reyes, Y., Nordgren, J., Svensson, L., de Silva, A. M., PREMKUMAR, L., Becker-Dreps, S.
10.1101/2021.04.28.21256122 — Posted: 2021-04-29
Surging COVID-19 in Bangladesh driven by B.1.351 variant
Brum, E., Saha, S., Sania, A., Tanmoy, A. M., Hooda, Y., Tanni, A., Goswami, S., Sium, S. M. A., Sajib, M. S. I., Malaker, R., Islam, S., Sarker, N., Saha, S. K., Chowdhury, S., Haddou, Y., Ferguson, E. A., Kundegorski, M., Purno, N., Tasneem, M., Arifeen, S. E., Alamgir, A. S. M., Chowdhury, A., Hampson, K.
10.1101/2021.04.27.21255706 — Posted: 2021-04-29
Large university with high COVID-19 incidence did not increase risk to non-student population
Bharti, N., Lambert, B., Exten, C., Faust, C., Ferrari, M., Robinson, A.
10.1101/2021.04.27.21255023 — Posted: 2021-04-29
SARS-CoV-2 infections in nasal epithelial cells from smokers versus non-smokers
Essaidi-Laziosi, M., Torriani, G., Alvarez, C., Kaiser, L., Eckerle, I.
10.1101/2021.04.28.21255760 — Posted: 2021-04-29
The herbal combination of Sugarcane, Black Myrobalan, and mastic as a supplementary treatment for COVID-19: a randomized clinical trial
Hashemi Shiri, A., Rayatdoost, E., Afkhami, H., Ravanshad, R., Hosseini, S. E., Kalani, N., Raoufi, R.
10.1101/2021.04.27.21256221 — Posted: 2021-04-28
Prophylactic protection against respiratory viruses conferred by a prototype live attenuated influenza virus vaccine.
Rathnasinghe, R., Salvatore, M., Zheng, H., Jangra, S., Kehrer, T., Mena, I., Schotsaert, M., Muster, T., Palese, P., Garcia-Sastre, A.
10.1101/2021.04.28.441797 — Posted: 2021-04-28
Nucleic acid delivery of immune-focused SARS-CoV-2 nanoparticles drive rapid and potent immunogenicity capable of single-dose protection
Konrath, K., Liaw, K., Wu, Y., Zhu, X., Walker, S., Xu, Z., Schultheis, K., Chokkalingam, N., Tursi, N. J., Du, J., Sullivan, M., Purwar, M., Moore, A., Machado, V., Maricic, I., Reuschel, E., Frase, D., Iffland, C., Broderick, K., Humeau, L., Smith, T., Pallesen, J., Weiner, D. B., Kulp, D. W.
10.1101/2021.04.28.441474 — Posted: 2021-04-28
Regulation of Lysosome-Associated Membrane Protein 3 (LAMP3) in Lung Epithelial Cells by Coronaviruses (SARS-CoV-1/2) and Type I Interferon Signaling
Chilakamarti, R.
10.1101/2021.04.28.441840 — Posted: 2021-04-28

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).